Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 21, 2022; 28(39): 5764-5783
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5764
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5764
Table 1 Characteristics of enrolled population in the metabolic profiling study
Clinical parameters | PBC (n = 54) | AIH (n = 26) | Control (n = 30) | P value (PBC vs control) | P value (AIH vs control) | P value (PBC vs AIH) |
Age (mean, range) (yr), n | 56 (38-73) | 54.6 (17-75) | 54.9(34-70) | 0.922 | 0.805 | 0.890 |
Sex (Male/Female), n | 7/47 | 3/23 | 4/26 | - | - | - |
AST (U/L) median, range | 113.3 (14-1300) | 168.8 (23-961) | 23.3 (7-38) | < 0.001 | < 0.001 | 0.423 |
ALT (U/L) median, range | 95.9 (12-734) | 153.3 (10-780) | 19.0 (7-39) | < 0.001 | < 0.001 | 0.125 |
ALP (U/L) median, range | 292.4 (55-953) | 240.1 (46-795) | 73.6 (32-116) | < 0.001 | < 0.001 | 0.123 |
γ-GT (U/L) median, range | 299.4 (32-1631) | 245.2 (26-957) | 21.1 (9-77) | < 0.001 | < 0.001 | 0.377 |
TBA (μmol/L) median, range | 60.0 (2.7-295.7) | 126.0 (1.1-1335) | - | - | - | 0.696 |
TBiL (μmol/L) median, range | 65.5 (5.6-825.8) | 89.1 (6.5-543.9) | 10.9 (6.3-19.5) | < 0.001 | < 0.001 | 0.481 |
DBIL (μmol/L) median range | 35.9 (2.4-407.4) | 52.9 (2.1-300.8) | 3.3 (0.4-6) | < 0.001 | < 0.001 | 0.648 |
Liver cirrhosis (%) | 65 (35/54) | 62 (16/26) | - | - | - | - |
Liver biopsy (%) | 18 (10/54) | 53 (14/26) | - | - | - | - |
Positive of AMA (%) | 81 (44/54) | 0 (0/26) | - | - | - | - |
Positive of ANA (%) | 61 (33/54) | 100 (26/26) | - | - | - | - |
- Citation: Ma ZH, Wang XM, Wu RH, Hao DL, Sun LC, Li P, Niu JQ. Serum metabolic profiling of targeted bile acids reveals potentially novel biomarkers for primary biliary cholangitis and autoimmune hepatitis. World J Gastroenterol 2022; 28(39): 5764-5783
- URL: https://www.wjgnet.com/1007-9327/full/v28/i39/5764.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i39.5764